Results from two major clinical trials presented at ACC (PARIS and PRINCETON, NJ, MARCH 9, 2005) Results of two major clinical trials showed that the antiplatelet agent clopidogrel, given on top of standard therapy, provided significant benefits to patients with acute ST-segment elevation myocardial infarction (STEMI), a certain kind of heart attack. Results of the COMMIT/CCS-2 (ClOpidogrel
Pfizer Inc. and the sanofi-aventis Group announced today that the United States Food and Drug Administration (FDA) has accepted for filing a new drug application for Exubera® (inhaled human insulin powder). Exubera®, a dry powder form of insulin that is inhaled into the lungs prior to eating, using a specially designed inhalation device, has been studied in more than 3,500 patients, some for o
Tommy Olin, commercial operations director, med ansvar för sanofi-aventis sälj- och marknadsorganisation har valt att lämna företaget för att gå vidare i en ny karriär utanför organisationen. Han lämnar sanofi-aventis vid månadsskiftet. För ytterligare information kontakta Annette Hedman, tf informationsanvarig, 08-470 18 52 eller 070-289 88 64. Koncernen sanofi-aventis är det tredje störst
Sanofi-aventis announced today that he has received marketing approval from the United States Food and Drug Administration for a new formulation of Eloxatin® (oxaliplatin for injection). This new formulation, Eloxatin® INJECTION, is a clear, preservative-free, colorless solution which does not require reconstitution. Eloxatin® INJECTION offers additional benefit and convenience to physicians an
TWO STUDIES DEMONSTRATE SIGNIFICANT BENEFIT OF ELOXATIN BASED CHEMOTHERAPY COMBINED WITH BEVACIZUMAB IN ADVANCED COLORECTAL CANCER Positive Results of TREE-2 and ECOG 3200 Trials Presented at the 2005 Gastrointestinal Cancers Symposium in Hollywood, Florida Sanofi-aventis (NYSE: SNY) announced today preliminary results of two large prospective trials evaluating the safety and efficacy of E
Sanofi-aventis gains market share from year one After consultation with the stock market authorities in France and the United States, sanofi-aventis has retained August 20 as the date of first consolidation. In 2004, sanofi-aventis generated consolidated net sales of 15,043 million euros compared with 8,048 million euros in 2003. In the fourth quarter of 2004, sanofi-aventis consolidated net
EU-kommissionen har godkänt sanofi-aventis läkemedel Taxotere (docetaxel) för adjuvant behandling, det vill säga direkt efter operation, vid tidig körtelpositiv bröstcancer. Kommissionens beslut baseras på resultatet av en stor långtidsstudie som visar på både en ökad överlevnad och minskad risk för återfall vid behandling med Taxotere. - Detta är framsteg vad gäller bröstcancerbehandling. Resu
Sanofi-aventis organizes today, January 25, 2005, a solidarity day in 300 sanofi-aventis sites worldwide to allow Group collaborators to take part in actions undertaken with partner aid agencies in the tsunami-stricken countries. Each employee will be able to share in the movement of solidarity by opting, either to make financial donation to the projects of the villages twinned with his or her
Sanofi-aventis has been notified that its patent in the UK issued from its European Patent claiming the active ingredient in its Plavix® product has been challenged by Aircoat, Ltd., a Scottish company, in a Scottish Court. Sanofi-aventis believes Aircoat's arguments to be without merit, and will vigorously defend its patent. Forward-looking statements: This press release contains forward-look
Rhodia announced today that it has commenced legal proceedings in the United States of America and Brazil against sanofi-aventis as former owner or operator of the Silver Bow (United States of America) and Cubatao (Brazil) sites to seek to obtain compensation for environmental liabilities related to these two sites. Aventis and Rhodia signed a final settlement agreement on March 27, 2003 pursua
According to a decision by the European Commission announced today, various producers of MCAA (monochloroacetic acid), an organic chemical used as intermediate in the manufacture of various products, have been fined. This decision was made further to an investigation regarding alleged arrangements affecting competition in certain markets for MCAA. Among those producers, Hoechst, an affiliate of
Sanofi-aventis announced today that the European Commission has approved 2 new indications for Taxotere® (docetaxel) Injection Concentrate for treatment of breast cancer. The first granted TAXOTERE , in combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer. A second granted TAXOTERE , in combination with Herceptin (tr
